270 related articles for article (PubMed ID: 20098449)
1. Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily.
Flyvbjerg A
Nat Rev Endocrinol; 2010 Feb; 6(2):94-101. PubMed ID: 20098449
[TBL] [Abstract][Full Text] [Related]
2. Complement activation and diabetic vascular complications.
Østergaard J; Hansen TK; Thiel S; Flyvbjerg A
Clin Chim Acta; 2005 Nov; 361(1-2):10-9. PubMed ID: 15996650
[TBL] [Abstract][Full Text] [Related]
3. The role of the complement system in diabetic nephropathy.
Flyvbjerg A
Nat Rev Nephrol; 2017 May; 13(5):311-318. PubMed ID: 28262777
[TBL] [Abstract][Full Text] [Related]
4. Serum osteoprotegerin and tumor necrosis factor related apoptosis inducing-ligand (TRAIL) are elevated in type 2 diabetic patients with albuminuria and serum osteoprotegerin is independently associated with the severity of diabetic nephropathy.
Chang YH; Lin KD; He SR; Hsieh MC; Hsiao JY; Shin SJ
Metabolism; 2011 Aug; 60(8):1064-9. PubMed ID: 21251686
[TBL] [Abstract][Full Text] [Related]
5. A role of the TRAIL-TRAIL receptor system in the pathogenesis of diabetes.
Vaccarezza M; Delbello G; Zauli G
Acta Biomed; 2007; 78 Suppl 1():262-7. PubMed ID: 17465340
[TBL] [Abstract][Full Text] [Related]
6. The osteoprotegerin/tumor necrosis factor related apoptosis-inducing ligand axis in the kidney.
Candido R
Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):69-74. PubMed ID: 24247823
[TBL] [Abstract][Full Text] [Related]
7. TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets?
Bernardi S; Voltan R; Rimondi E; Melloni E; Milani D; Cervellati C; Gemmati D; Celeghini C; Secchiero P; Zauli G; Tisato V
Clin Sci (Lond); 2019 May; 133(10):1145-1166. PubMed ID: 31097613
[TBL] [Abstract][Full Text] [Related]
8. Increased Autoreactivity of the Complement-Activating Molecule Mannan-Binding Lectin in a Type 1 Diabetes Model.
Østergaard JA; Ruseva MM; Malik TH; Hoffmann-Petersen IT; Pickering MC; Thiel S; Hansen TK
J Diabetes Res; 2016; 2016():1825738. PubMed ID: 26977416
[TBL] [Abstract][Full Text] [Related]
9. Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes.
O'Sullivan EP; Ashley DT; Davenport C; Devlin N; Crowley R; Agha A; Thompson CJ; O'Gorman D; Smith D
Diabetes Metab Res Rev; 2010 Sep; 26(6):496-502. PubMed ID: 20809534
[TBL] [Abstract][Full Text] [Related]
10. Vascular calcification in type-2 diabetes and cardiovascular disease: Integrative roles for OPG, RANKL and TRAIL.
Harper E; Forde H; Davenport C; Rochfort KD; Smith D; Cummins PM
Vascul Pharmacol; 2016 Jul; 82():30-40. PubMed ID: 26924459
[TBL] [Abstract][Full Text] [Related]
11. Von Willebrand factor in diabetic angiopathy.
Kessler L; Wiesel ML; Attali P; Mossard JM; Cazenave JP; Pinget M
Diabetes Metab; 1998 Sep; 24(4):327-36. PubMed ID: 9805643
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes.
Shin JY; Shin YG; Chung CH
Diabetes Care; 2006 Jul; 29(7):1664-6. PubMed ID: 16801598
[No Abstract] [Full Text] [Related]
13. High Expression of Complement Components in the Kidneys of Type 2 Diabetic Rats With Diabetic Nephropathy.
Huang Y; Xu J; Wu X; Chen X; Bai X; Zhuang Y; Fang J; Lin X
Front Endocrinol (Lausanne); 2019; 10():459. PubMed ID: 31338070
[No Abstract] [Full Text] [Related]
14. [Cardiovascular protection of diabetic patient with chronic renal disease and particular case of end-stage renal disease in elderly patients].
Zaoui P; Hannedouche T; Combe C
Nephrol Ther; 2017 Jun; 13(6S):6S16-6S24. PubMed ID: 29463395
[TBL] [Abstract][Full Text] [Related]
15. Mannose-binding lectin (MBL) and vascular complications in diabetes.
Hansen TK
Horm Metab Res; 2005 Apr; 37 Suppl 1():95-8. PubMed ID: 15918118
[TBL] [Abstract][Full Text] [Related]
16. The role of the osteoprotegerin/RANKL/RANK system in diabetic vascular disease.
Grigoropoulou P; Eleftheriadou I; Zoupas C; Tentolouris N
Curr Med Chem; 2011; 18(31):4813-9. PubMed ID: 21919846
[TBL] [Abstract][Full Text] [Related]
17. Osteoprotegerin and osteoprotegerin/TRAIL ratio are associated with cardiovascular dysfunction and mortality among patients with renal failure.
Kuźniewski M; Fedak D; Dumnicka P; Stępień E; Kuśnierz-Cabala B; Cwynar M; Sułowicz W
Adv Med Sci; 2016 Sep; 61(2):269-275. PubMed ID: 27128817
[TBL] [Abstract][Full Text] [Related]
18. Eye complications and markers of morbidity and mortality in long-term type 1 diabetes.
Grauslund J
Acta Ophthalmol; 2011 Feb; 89 Thesis 1():1-19. PubMed ID: 21443578
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of antihypertensive therapy in decreasing renal and cardiovascular complications in diabetes mellitus.
Nosadini R; Abaterusso C; Dalla Vestra M; Bortoloso E; Saller A; Bruseghin M; Sfriso A; Trevisan M
Nephrol Dial Transplant; 1998; 13 Suppl 8():44-8. PubMed ID: 9870425
[TBL] [Abstract][Full Text] [Related]
20. Association between mannose-binding lectin and vascular complications in type 1 diabetes.
Hansen TK; Tarnow L; Thiel S; Steffensen R; Stehouwer CD; Schalkwijk CG; Parving HH; Flyvbjerg A
Diabetes; 2004 Jun; 53(6):1570-6. PubMed ID: 15161763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
